Rationale and Study Design of CIRCULATE-NORTH AMERICA in CRC

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.